Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Precision Medicine Market Size, Share, and Trends - Global Forecast 2026-2032 | AI, Genomics, and Companion Diagnostics Drive 13.34% CAGR Toward USD 324.92 Billion

globenewswire.com
ABBV AbbVie Inc. is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards AbbVie. AMGN Amgen Inc. is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Amgen. AZN AstraZeneca PLC is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards AstraZeneca. BMY Bristol-Myers Squibb Company is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Bristol-Myers Squibb. EXAS Exact Sciences Corporation is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Exact Sciences. GILD Gilead Sciences, Inc. is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Gilead Sciences. GH Guardant Health, Inc. is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Guardant Health. ILMN Illumina, Inc. is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Illumina. JNJ Johnson & Johnson is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Johnson & Johnson. MD Medtronic PLC is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Medtronic. MRK Merck KGaA is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Merck KGaA. NTRA Natera Inc. is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Natera. NVS Novartis AG is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Novartis. PFE Pfizer, Inc. is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Pfizer. DGX Quest Diagnostics Incorporated is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Quest Diagnostics. SNY Sanofi SA is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Sanofi. TEVA Teva Pharmaceutical Industries Ltd. is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Teva. TMO Thermo Fisher Scientific Inc. is listed as a company profile in a report about the precision medicine market, indicating its potential involvement in the sector. The article does not provide specific sentiment towards Thermo Fisher Scientific.

Precision Medicine Market Size, Share, and Trends - Global Forecast 2026-2032 | AI, Genomics, and Companion Diagnostics Drive 13.34% CAGR Toward USD 324.92 Billion Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Precision Medicine Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

This market research report examines the global precision medicine market, which is projected to reach USD 152.68 billion in 2026 and expand at a CAGR of 13.34% to USD 324.92 billion by 2032. It analyzes the shift from population-based healthcare toward biomarker-driven therapies, genomic testing, companion diagnostics, pharmacogenomics, molecular imaging, and data-enabled clinical decision support.

Market Overview and Growth Drivers

Precision medicine aligns prevention, diagnosis, and treatment with each patient's biological, environmental, and lifestyle characteristics. Adoption is strongest across oncology, rare diseases, immunology, cardiology, neurology, and infectious diseases, where validated biomarkers increasingly guide treatment selection and monitoring.

Major initiatives-including NIH All of Us, the UK 100,000 Genomes Project, Genome India, Gulf national genome programs, and Europe's 1+ Million Genomes framework-demonstrate growing institutional commitment. The report's market forecasts and adoption analysis support strategic planning, investment prioritization, and opportunity identification across healthcare and life sciences.

Transformative Market Shifts

The industry is progressing from isolated genetic tests to integrated ecosystems combining multi-omics, real-world evidence, electronic health records, imaging, wearable data, and longitudinal monitoring. Key growth technologies include:

Regulators increasingly support biomarker-based drug development, while payers demand evidence of clinical utility, cost-effectiveness, and equitable access. These insights enable organizations to anticipate commercialization risks and align product development with evolving regulatory and reimbursement expectations.

Artificial Intelligence in Precision Medicine

Artificial intelligence is generating value across genomics, transcriptomics, proteomics, pathology, radiology, claims data, and clinical documentation. Applications include variant interpretation, patient stratification, drug-target discovery, clinical trial matching, adverse-event prediction, and treatment-response forecasting.

Successful deployment depends on curated datasets, clinician oversight, model transparency, bias testing, cybersecurity, and continuous monitoring. Federated learning, synthetic data, and privacy-enhancing technologies are also enabling collaboration while protecting sensitive patient information.

Regional and Economic Group Insights

ASEAN offers an emerging growth corridor, while the GCC stands out for government-backed genomics and AI investment. BRICS markets provide population scale and sequencing potential, whereas the G7 leads in diagnostics, regulatory science, AI governance, and biopharma innovation. Comparative regional intelligence can inform market-entry strategies and partnership selection.

Country-Level Highlights

The United States leads in research funding, commercial testing, regulatory guidance, and biopharma pipelines. Canada, Mexico, and Brazil are advancing through research networks, laboratory modernization, cancer genomics, and rare disease programs.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong genomic and clinical research capabilities. China, India, Japan, Australia, and South Korea are expanding sequencing, digital healthcare, oncology innovation, pharmacogenomics, and AI-enabled care.

Strategic Priorities for Industry Leaders

Key Takeaways from This Report

Key Attributes:

Key Topics Covered:

1. Preface

1.1. Objectives of the Study

1.2. Market Definition

1.3. Market Segmentation & Coverage

1.4. Years Considered for the Study

1.5. Currency Considered for the Study

1.6. Language Considered for the Study

1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction

2.2. Research Design

2.2.1. Primary Research

2.2.2. Secondary Research

2.3. Research Framework

2.3.1. Qualitative Analysis

2.3.2. Quantitative Analysis

2.4. Market Size Estimation

2.4.1. Top-Down Approach

2.4.2. Bottom-Up Approach

2.5. Data Triangulation

2.6. Research Outcomes

2.7. Research Assumptions

2.8. Research Limitations

3. Executive Summary

3.1. Introduction

3.2. CXO Perspective

3.3. New Revenue Opportunities

3.4. Next-Generation Business Models

3.5. Industry Roadmap

4. Market Overview

4.1. Introduction

4.2. Industry Ecosystem & Value Chain Analysis

4.2.1. Supply-Side Analysis

4.2.2. Demand-Side Analysis

4.2.3. Stakeholder Analysis

4.3. Market Dynamics

4.3.1. Key Drivers

4.3.2. Key Restraints

4.3.3. Key Opportunities

4.3.4. Key Challenges

4.4. Porter's Five Forces Analysis

4.5. PESTLE Analysis

4.6. Market Outlook

4.6.1. Near-Term Market Outlook (0-2 Years)

4.6.2. Medium-Term Market Outlook (3-5 Years)

4.6.3. Long-Term Market Outlook (5-10 Years)

4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective

5.2. Consumer Experience Benchmarking

5.3. Opportunity Mapping

5.4. Distribution Channel Analysis

5.5. Pricing Trend Analysis

5.6. Regulatory Compliance & Standards Framework

5.7. ESG & Sustainability Analysis

5.8. Disruption & Risk Scenarios

5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Precision Medicine Market, by Product Type

7.1. Introduction

7.2. Diagnostics

7.2.1. Companion Diagnostics

7.2.2. Genetic Testing

7.2.3. Liquid Biopsy

7.2.4. Molecular Diagnostics

7.2.5. Point-of-Care Testing

7.3. Software & Data Analytics

7.4. Therapeutics

7.4.1. Cell Therapy

7.4.2. Gene Therapy

7.4.3. Immunotherapy

7.4.4. Protein Replacement Therapy

7.4.5. RNA-Based Therapy

7.4.6. Targeted Therapy

8. Precision Medicine Market, by Biomarker Type

8.1. Introduction

8.2. Genomic Biomarkers

8.3. Proteomic Biomarkers

8.4. Metabolomic Biomarkers

8.5. Epigenetic Biomarkers

9. Precision Medicine Market, by Route of Administration

9.1. Introduction

9.2. Oral

9.3. Injectable

9.4. Intravenous

9.5. Subcutaneous

10. Precision Medicine Market, by Application

10.1. Introduction

10.2. Autoimmune Diseases

10.3. Cardiology

10.4. Infectious Diseases

10.5. Neurology

10.6. Oncology

10.7. Rare & Genetic Disorders

10.8. Respiratory Diseases

11. Precision Medicine Market, by End User

11.1. Introduction

11.2. Biopharmaceutical & Biotechnology Companies

11.3. Diagnostic Laboratories

11.4. Hospitals & Clinics

11.5. Research Institutes

12. Precision Medicine Market, by Region

12.1. Introduction

12.2. Asia-Pacific

12.3. Europe

12.4. North America

12.5. Latin America

12.6. Africa

12.7. Middle East

13. Precision Medicine Market, by Group

13.1. Introduction

13.2. NATO

13.3. G7

13.4. BRICS

13.5. European Union

13.6. ASEAN

13.7. GCC

14. Precision Medicine Market, by Country

14.1. Introduction

14.2. China

14.3. United States

14.4. Japan

14.5. India

14.6. Germany

14.7. United Kingdom

14.8. Australia

14.9. France

14.10. South Korea

14.11. Italy

14.12. Canada

14.13. Russia

14.14. Brazil

14.15. Mexico

14.16. Spain

15. Competitive Landscape

15.1. Market Share Analysis, 2025

15.2. Market Concentration Analysis, 2025

15.2.1. Concentration Ratio (CR)

15.2.2. Herfindahl Hirschman Index (HHI)

15.3. Recent Developments & Impact Analysis, 2025

15.4. Product Portfolio Analysis, 2025

15.5. Benchmarking Analysis, 2025

16. Company Profiles

16.1. AbbVie Inc.

16.2. Amgen Inc.

16.3. Aranscia, LLC

16.4. AstraZeneca PLC

16.5. biocrates life sciences ag

16.6. bioMerieux S.A.

16.7. Bristol-Myers Squibb Company

16.8. Caris Life Sciences

16.9. Exact Sciences Corporation

16.10. F. Hoffmann-La Roche AG

16.11. Gilead Sciences, Inc.

16.12. Guardant Health, Inc.

16.13. healthOme, Inc.

16.14. Hitachi High-Tech Corporation

16.15. Illumina, Inc.

16.16. Johnson & Johnson

16.17. Laboratory Corporation of America Holdings

16.18. Medtronic PLC

16.19. Merck KGaA

16.20. N-Power Medicine, Inc.

16.21. Natera Inc.

16.22. NeoGenomics, Inc.

16.23. Novartis AG

16.24. Pfizer, Inc.

16.25. Precision Medicine Group, LLC

16.26. QIAGEN N.V.

16.27. Quest Diagnostics Incorporated

16.28. Sanofi SA

16.29. Strata Oncology, Inc.

16.30. Tempus AI, Inc.

16.31. Teva Pharmaceutical Industries Ltd.

16.32. Thermo Fisher Scientific Inc.

16.33. ZS Associates, Inc.

17. Key Experts

List of Figures [21]

List of Tables [327]

For more information about this report visit https://www.researchandmarkets.com/r/uwtww7

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.